Hemoglobin Disorders
Authors:
- 24 October 2024
- book chapter
- Published by Springer Nature
- p. 159-174
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell DiseaseNew England Journal of Medicine, 2023
- Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell DiseaseNew England Journal of Medicine, 2022
- A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-ThalassemiaNew England Journal of Medicine, 2020
- Haemoglobinopathy Diagnosis2020
- A Phase 3 Randomized Trial of Voxelotor in Sickle Cell DiseaseNew England Journal of Medicine, 2019
- A Phase 3 Trial of l -Glutamine in Sickle Cell DiseaseNew England Journal of Medicine, 2018
- Gene Therapy in Patients with Transfusion-Dependent β-ThalassemiaNew England Journal of Medicine, 2018
- Crizanlizumab for the Prevention of Pain Crises in Sickle Cell DiseaseNew England Journal of Medicine, 2017
- Fortnightly review: The thalassaemiasBMJ, 1997
- Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell AnemiaNew England Journal of Medicine, 1995